Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) were down 6.2% on Wednesday. The stock traded as low as $12.5319 and last traded at $12.5319. 735 shares were traded during mid-day trading, a decline of 81% from the average session volume of 3,773 shares. The stock had previously closed at $13.36.
Innovent Biologics Price Performance
The stock has a 50-day simple moving average of $12.46 and a 200-day simple moving average of $11.31.
Innovent Biologics Company Profile
Innovent Biologics, Inc is a China-based biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines and biosimilars. The company’s research and development activities primarily address oncology, autoimmune diseases, metabolic disorders and other serious medical conditions.
Innovent’s portfolio includes therapies such as TYVYT (sintilimab), an immunotherapy used in certain cancer treatments, and olverembatinib, a targeted therapy for specific forms of chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Innovent Biologics
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
